NPS reports positive results from Phase III study of Gattex.

The article reports on the positive results from NPS Pharmaceuticals Inc.'s 28-week blind phase III extension study of Gattex for short bowel syndrome patients who are dependent upon parenteral nutrition (PN). Patients treated with low-dose Gattex demonstrated a mean 51 percent reduction in PN volume from pretreatment baseline to the end of 52 weeks, and those treated with high-dose Gattex experienced a mean 24 percent reduction.